APA (7th ed.) Citation

Oubari, S., Hegenbart, U., Schoder, R., Steinhardt, M., Papathanasiou, M., Rassaf, T., . . . Carpinteiro, A. (2024). Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica, 109(1), . https://doi.org/10.3324/haematol.2023.283325

Chicago Style (17th ed.) Citation

Oubari, Sara, et al. "Daratumumab in First-line Treatment of Patients with Light Chain Amyloidosis and Mayo Stage IIIb Improves Treatment Response and Overall Survival." Haematologica 109, no. 1 (2024). https://doi.org/10.3324/haematol.2023.283325.

MLA (9th ed.) Citation

Oubari, Sara, et al. "Daratumumab in First-line Treatment of Patients with Light Chain Amyloidosis and Mayo Stage IIIb Improves Treatment Response and Overall Survival." Haematologica, vol. 109, no. 1, 2024, https://doi.org/10.3324/haematol.2023.283325.